Navigation Links
Answer to troublesome question of why some genetic assoc. studies have failed replication attempts
Date:4/3/2008

childhood and diminishes after age 45.

"This is important because it demonstrates that genetic effects can vary over time," said Jessica Lasky-Su, Instructor at Harvard Medical School and Brigham and Women's Hospital. "In this example, the marker may increase obesity in early life and then as time goes on, other effects become stronger, and the influence of this marker diminishes. It is likely that many other genetic variants also act in this fashion." Lasky-Su is co-lead author of the study with Helen Lyon of Children's Hospital Boston.

To test rs1455832 further, the researchers examined its association with obesity and with age in eight other study populations comprising 13,584 individuals. Five international centers participated, including studies from Costa Rica, Greece, Poland, Iceland, and Germany. The interaction was observed in five of the eight replicate samples with statistically significant results. The authors note that this interaction would have been missed in all but one of the replication samples if they had failed to incorporate the age-dependent effect in the association analysis.

Said Lange, "We are now in an era where scanning entire genomes for associations with diseases is rapid. In assessing the resulting data, it will be important for scientists to keep in mind the significance of age, otherwise findings may not be replicated or may be overlooked entirely."

The importance of age-dependent genetic effects for BMI was suggested in a 2003 paper published by researchers at the University of Texas MD Anderson Cancer Center in the European Journal of Human Genetics that described a genome-wide scan for genes related to BMI. However, the incorporation of age-dependent genetic effects for BMI into genetic analyses remains uncommon.


'/>"/>

Contact: Christina Roache
croache@hsph.harvard.edu
617-432-6052
Harvard School of Public Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Answering challenges of life in extreme environments research
2. Can you rescue a rainforest? The answer may be yes
3. MIT: No easy answers in evolution of human language
4. Fungus genome yielding answers to protect grains, people and animals
5. A fossilized giant rhino bone questions the isolation of Anatolia, 25 million years ago
6. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
7. Cold Spring Harbor Laboratory to play central role addressing key questions in plant biology
8. UA-led research team awarded $50 million to solve plant biologys grand challenge questions
9. Computer-based tool aids research, helps thwart questionable publication practices
10. Sticky questions tackled in gecko research
11. New research on structure of bones raises questions for treatment of osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its ... the G2 model. The G2 sets a higher standard for ... human capital management solution. With plug-and-play installation, touch screen interface ... clock provides a robust time collection solution for the small ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces it ... Robbins for the 2015 International CES debut of the ... will be at the NXT-ID booth January 6th and ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... DIEGO , Nov. 14, 2013  Shareholder rights law firm ... Vical Incorporated (NASDAQ: VICL ) has filed a ... Court for the Southern District of California.  The complaint alleges ... Securities and Exchange Act of 1934 between February, 8, 2012 ...
... baboons at the Texas Biomedical Research Institute may help ... bisphosphonates are at-risk for atypical fractures in the long ... M. Havill, Ph.D. and colleagues at the Southwest Research ... and found differences in the microstructure of their femurs ...
... resistance is an international reality whose solution includes better ... disease physician. "The big problem is the overuse ... can they lead to side effects like rashes and ... of multidrug-resistant organisms," said Dr. Josѐ A. Vazquez, Chief ...
Cached Biology News:Attention Vical Incorporated Investors: Vical Misled Investors According to a Newly Filed Class Action 2New studies may explain fractures in some who take osteoporosis drugs 2Antibiotic resistance is a international issue that better education can address 2
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... announced today that it has completed patient enrollment ... company,s investigational,once-daily oral anti-cancer drug, for the second-line ... studies -- ZODIAC (ZACTIMA in,cOmbination with Docetaxel In ... Alimta in Lung cancer) -- are the second ...
... DIEGO, March 12 Volcano Corporation,(Nasdaq: VOLC ... and,functional measurement (FM) products designed to enhance the ... said today that it,will be participating in the ... Monday, March 17., The presentation by Scott ...
... March 12 Allergy Standards LTD,("ASL"), the internationally ... its participation at the 2008 American Academy of,Allergy, ... in,Philadelphia, PA March 14th-18th., "The AAAAI conference ... research work in the asthma and allergy spaces," ...
Cached Biology Technology:AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 2AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 3Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast 2